Travere Therapeutics To Present Clinical Data From The Phase 1/2 COMPOSE Study Of Pegtibatinase At The Society For The Study Of Inborn Errors Of Metabolism Annual Symposium 2023
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics is set to present clinical data from the Phase 1/2 COMPOSE study of Pegtibatinase at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023.
August 24, 2023 | 8:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics' upcoming presentation of clinical data from the Phase 1/2 COMPOSE study of Pegtibatinase could potentially impact the company's stock.
The presentation of clinical data from a study can often influence a biotech company's stock. However, the direction of the impact is uncertain until the data is revealed and interpreted by the market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100